Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunocore Holdings plc - American Depositary Shares (NQ:IMCR)

32.30 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 163
Open 32.30
Bid (Size) 31.69 (100)
Ask (Size) 35.66 (100)
Prev. Close 32.30
Today's Range 32.30 - 32.30
52wk Range 27.55 - 40.71
Shares Outstanding 43,862,850
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore to present at upcoming investor conferences
From Immunocore Holdings plc
Via GlobeNewswire

Performance

YTD
-4.4%
-4.4%
1 Month
-10.3%
-10.3%
3 Month
+12.9%
+12.9%
6 Month
+7.5%
+7.5%
1 Year
-3.3%
-3.3%

More News

Read More
News headline image
Immunocore Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
Immunocore (NASDAQ:IMCR) Q2 Revenue Beats but EPS Misses, Shares Tumble ↗
Via Chartmill
News headline image
Immunocore reports second quarter financial results and provides a business update
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore to report second quarter 2026 financial results and host call on August 6, 2026
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore reports first quarter financial results and provides a business update
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore to present at upcoming investor conferences
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore (IMCR) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Immunocore reports fourth quarter and full year 2025 financial results and provides a business update
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore announces R&D leadership evolution
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore (IMCR) Q2 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Immunocore to present at upcoming investor conferences
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore presents Phase 1 data for hepatitis B candidate at AASLD’s The Liver Meeting
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore reports third quarter financial results and provides a business update
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Growth Picks: 3 Low-Cost Stocks That Could Double in Value ↗
Via MarketBeat
News headline image
Immunocore to present at upcoming investor conferences
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore (IMCR) Q2 Revenue Jumps 30% ↗
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
Immunocore Holdings PLC (NASDAQ:IMCR) Beats Q2 2025 Revenue and EPS Estimates with Strong KIMMTRAK Sales Growth ↗
Via Chartmill

Frequently Asked Questions

Is Immunocore Holdings plc - American Depositary Shares publicly traded?
Yes, Immunocore Holdings plc - American Depositary Shares is publicly traded.
What exchange does Immunocore Holdings plc - American Depositary Shares trade on?
Immunocore Holdings plc - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Immunocore Holdings plc - American Depositary Shares?
The ticker symbol for Immunocore Holdings plc - American Depositary Shares is IMCR on the Nasdaq Stock Market
What is the current price of Immunocore Holdings plc - American Depositary Shares?
The current price of Immunocore Holdings plc - American Depositary Shares is 32.30
When was Immunocore Holdings plc - American Depositary Shares last traded?
The last trade of Immunocore Holdings plc - American Depositary Shares was at 09/17/26 04:00 PM ET
What is the market capitalization of Immunocore Holdings plc - American Depositary Shares?
The market capitalization of Immunocore Holdings plc - American Depositary Shares is 1.42B
How many shares of Immunocore Holdings plc - American Depositary Shares are outstanding?
Immunocore Holdings plc - American Depositary Shares has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.